Puma Biotechnology
Puma Biotechnology Receives US FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | SpringerLink
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Puma Biotechnology, Inc. - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Dose escalation for mitigating diarrhea: Ranked tolerability assessment of antidiarrheal regimens in patients receiving neratin
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
PUMA BIOTECHNOLOGY, INC.
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Neratinib (HKI-272) | ≥99%(HPLC) | Selleck | HER2 inhibitor
PUMA Background
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
